Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer’s disease

[1]  J. Whitwell,et al.  Alzheimer's disease neuroimaging , 2018, Current opinion in neurology.

[2]  V. Baud,et al.  Post-Translational Modifications of RelB NF-κB Subunit and Associated Functions , 2016, Cells.

[3]  A. Saykin,et al.  Hippocampal Sclerosis of Aging, a Common Alzheimer's Disease 'Mimic': Risk Genotypes are Associated with Brain Atrophy Outside the Temporal Lobe. , 2016, Journal of Alzheimer's disease : JAD.

[4]  C. Jack,et al.  APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern , 2015, Alzheimer's & Dementia.

[5]  H. Zetterberg,et al.  Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia , 2015, Alzheimer's & dementia.

[6]  R. Green,et al.  Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans , 2015, Alzheimer's & Dementia.

[7]  Michael W. Weiner,et al.  Comparison of multi-sample variant calling methods for whole genome sequencing , 2014, 2014 8th International Conference on Systems Biology (ISB).

[8]  J. Provias,et al.  The Role of the Blood-Brain Barrier in the Pathogenesis of Senile Plaques in Alzheimer's Disease , 2014, International journal of Alzheimer's disease.

[9]  Erick R. Scott,et al.  Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer’s disease , 2013, Nature.

[10]  Nick C Fox,et al.  Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease , 2013, Nature Genetics.

[11]  J. Hardy,et al.  TREM2 and neurodegenerative disease. , 2013, The New England journal of medicine.

[12]  Jason J. Corneveaux,et al.  Identification of functional variants from whole-exome sequencing, combined with neuroimaging genetics , 2013, Molecular Psychiatry.

[13]  L. Fratiglioni,et al.  The influence of APOE and TOMM40 polymorphisms on hippocampal volume and episodic memory in old age , 2013, Front. Hum. Neurosci..

[14]  Jason J. Corneveaux,et al.  Whole-exome sequencing and imaging genetics identify functional variants for rate of change in hippocampal volume in mild cognitive impairment , 2013, Molecular Psychiatry.

[15]  J. A. Barreto,et al.  DARC (Duffy) and BCAM (Lutheran) reduced expression in thyroid cancer. , 2013, Blood cells, molecules & diseases.

[16]  Huaxi Xu,et al.  Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy , 2013, Nature Reviews Neurology.

[17]  A. Singleton,et al.  TREM2 variants in Alzheimer's disease. , 2013, The New England journal of medicine.

[18]  John Hardy,et al.  TOMM40 association with Alzheimer disease: tales of APOE and linkage disequilibrium. , 2012, Archives of neurology.

[19]  R. Tanzi.  The genetics of Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[20]  Paul K Crane,et al.  Comprehensive search for Alzheimer disease susceptibility loci in the APOE region. , 2012, Archives of neurology.

[21]  M. Rieder,et al.  Optimal unified approach for rare-variant association testing with application to small-sample case-control whole-exome sequencing studies. , 2012, American journal of human genetics.

[22]  M A Pericak-Vance,et al.  Genome-wide association study of Alzheimer's disease , 2012, Translational Psychiatry.

[23]  H. Arrighi,et al.  Prevalence of Apolipoprotein E4 Genotype and Homozygotes (APOE e4/4) among Patients Diagnosed with Alzheimer’s Disease: A Systematic Review and Meta-Analysis , 2011, Neuroepidemiology.

[24]  O. Combarros,et al.  Genetic variation in APOE cluster region and Alzheimer's disease risk , 2011, Neurobiology of Aging.

[25]  David M Holtzman,et al.  Association and expression analyses with single-nucleotide polymorphisms in TOMM40 in Alzheimer disease. , 2011, Archives of neurology.

[26]  Robert C. Green,et al.  The effect of TOMM40 poly-T length on gray matter volume and cognition in middle-aged persons with APOE ɛ3/ɛ3 genotype , 2011, Alzheimer's & Dementia.

[27]  E. Porcellini,et al.  Alzheimer's disease gene signature says: beware of brain viral infections , 2010, Immunity & Ageing.

[28]  S. Potkin,et al.  Genome-wide association study of CSF biomarkers Aβ1-42, t-tau, and p-tau181p in the ADNI cohort , 2010, Neurology.

[29]  Michael Weiner,et al.  Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort , 2010, NeuroImage.

[30]  Alkes L. Price,et al.  New approaches to population stratification in genome-wide association studies , 2010, Nature Reviews Genetics.

[31]  Anoop Arunagiri,et al.  CSF Biomarkers for Alzheimer's Disease Diagnosis , 2010, International journal of Alzheimer's disease.

[32]  W. Jagust,et al.  The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core , 2010, Alzheimer's & Dementia.

[33]  Mark E. Schmidt,et al.  The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans , 2010, Alzheimer's & Dementia.

[34]  A. Roses.  An inherited variable poly-T repeat genotype in TOMM40 in Alzheimer disease. , 2010, Archives of neurology.

[35]  Jason H. Moore,et al.  Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans , 2010, Alzheimer's & Dementia.

[36]  A D Roses,et al.  A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease , 2009, The Pharmacogenomics Journal.

[37]  Nick C Fox,et al.  The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.

[38]  D. Bennett,et al.  Alzheimer disease in the US population: prevalence estimates using the 2000 census. , 2003, Archives of neurology.

[39]  W. Pardridge,et al.  Selective Lutheran Glycoprotein Gene Expression at the Blood—Brain Barrier in Normal Brain and in Human Brain Tumors , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[40]  P. Baeuerle,et al.  Transcription factor NF-κB is activated in primary neurons by amyloid β peptides and in neurons surrounding early plaques from patients with Alzheimer disease , 1997 .

[41]  K. Engedal,et al.  The role of heredity in late-onset Alzheimer disease and vascular dementia. A twin study. , 1997, Archives of general psychiatry.

[42]  P. Baeuerle,et al.  Transcription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[43]  L. Ploughman,et al.  Heterogeneity testing for Alzheimer's disease within and between data sets , 1993, Genetic epidemiology.

[44]  P. S. St George-Hyslop,et al.  The BCL3 locus on chromosome 19 displays an informative microsatellite polymorphism. , 1992, Nucleic Acids Research.

[45]  M. Pericak-Vance,et al.  Linkage studies in familial Alzheimer disease: evidence for chromosome 19 linkage. , 1991, American journal of human genetics.